



For immediate release

July 28th, 2006

EDELIRIS announces successful achievement of medicinal chemistry collaboration with Pierre Fabre Urologie, an affiliate of Pierre Fabre Research Institute.

Lyon – July 25, 2006 – Based upon the completion of a medicinal chemistry project defined with Pierre Fabre chemists, Edelris announced today that successful achievement had been reached for the collaboration.

"A flexible working approach based on a 2-phase project and a high reactivity and deadline commitment from the Edelris team have contributed to the success of this project" said Dr. Philippe Schmitt, from Pierre Fabre. "We have been happy with the reliable quality of their work and look forward to working with Edelris again."

Dr. Jean-Yves Ortholand, CEO of Edelris, said "Our client-oriented mindset, recognized medchem expertise and flexibility of our team, are what gave us the opportunity to work with Pierre Fabre. It has enabled us to deliver results to them with the highest standards of quality and professionalism."

About Pierre Fabre Médicament

The Pierre Fabre Group, the second largest independent laboratory in France, employs some 8620 people, and achieved 1.48 billion euros in sales in 2005. Pierre Fabre Médicament, the pharmaceutical branch of the Pierre Fabre Group, made Research and Development its core business and the key to its future. With over 1 000 researchers, Pierre Fabre Médicament dedicates 25 % of its annual sales to R&D, in five major therapeutic areas in terms of public health: oncology (the priority R&D area of Pierre Fabre Médicament, with 50 % of all R&D expenses), central nervous system, cardiology, internal medicine/urology, dermatology.

About Edelris

EDELIRIS is a MedChem-oriented Research & Service based company, dedicated to the design and production of innovative, therapeutically relevant, natural-mimetic screening compounds. Aiming at the acceleration of the hit/lead discovery process in pharmaceutical and biotech research organizations, EDELIRIS uses its track-proven chemistry and drug discovery expertise to provide novelty to its customers with exclusive or non-exclusive small molecules and with efficient hit/lead optimization capabilities.

Several customers from pharmaceutical and biotechnology companies have already recognized the value and specificity of the EDELIRIS offer, accessing either its experienced MedChem services or its innovative natural-mimetic Keymical Collections™.

Contact

EDELIRIS s.a.s.

Jean-Yves Ortholand, CEO

tel: +33 (0)4 3756 1901

jean-yves.ortholand@edelris.com